Merck Ends Nemtabrutinib Program After Phase 3 Review

Merck discontinued the full BELLWAVE nemtabrutinib program for CLL, SLL and other hematologic cancers after an external data monitoring committee judged that benefit may not outweigh risk in Phase 3 BELLWAVE-011. Merck reviewed the…




